I. Jensen - Concepedia

Author

I. Jensen

Novo Holdings (Denmark)ORCID

Also Known As

Heiko Rohdjeß, I Jensen, I. Jensen, I.S. Jensen, Igor Ferrari Jensen, Ivar Jensen, Ivar S Jensen, Ivar S. Jensen

Publications

703

Citations

H-Index

Concepts

All Affiliations

Novo Holdings (Denmark)Rigshospitalet Aalborg University Hospital Hartford Hospital Doctors Company (United States)

About

I. Jensen is an author at Novo Holdings (Denmark) specializing in diabetes, physiology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	52
2	Engineering	1	1	35
3	Health Sciences	1	1	15
4	Biomedical Engineering	1	1	35
5	Biostatistics	1	1	35

I. Jensen

Publications

606

Citations

H-Index

Page 1

	Year	Citations
Carbohydrate and Lipid Metabolism of Skeletal Muscle in Type 2 Diabetic Patients K. Falholt, I. Jensen, S L Jensen, Diabetic Medicine	1988	124
Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients Daniel C. Malone, Rebecca Dean, R. Arjunji, Journal of Market Access & Health Policy	2019	92
In Vitro and In Vivo Potency of Insulin Analogues Designed for Clinical Use Aa. Vølund, Jens Brange, Kirsten Drejer, Diabetic Medicine	1991	75
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER) Rebecca Dean, I. Jensen, Phil Cyr, Journal of Market Access & Health Policy	2021	46
Action profiles of fast onset insulin analogues Lutz Heinemann, A. Starke, Lise G. Hedïng, Diabetologia Action ProfilesMedicineDiabetesPhysiologyInsulin Management	1990	37
Reconstructing the rate of appearance of subcutaneous insulin by deconvolution Claudio Cobelli, Andrea Mari, Stefano Del Prato, American Journal of Physiology-Endocrinology and Metabolism EngineeringBiosignal ProcessingInsulin ManagementPhysiologyDiabetes	1987	35
Dose constraints for whole breast radiation therapy based on the quality assessment of treatment plans in the randomised Danish breast cancer group (DBCG) HYPO trial Mette S. Thomsen, Martin Berg, S.J. Zimmermann, Clinical and Translational Radiation Oncology	2021	26
A Comparison of Human Ultralente‐and Lente‐based Twice‐daily Injection Regimens F. K. E. Tunbridge, Andrew Newens, P. D. Home, Diabetic Medicine	1989	25
Evaluating cost benefits of combination therapies for advanced melanoma I. Jensen, Emily Zacherle, Christopher Blanchette, Drugs in Context	2016	23
Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis I. Jensen, Thomas P. Lodise, Weihong Fan, Clinical Drug Investigation	2015	19

Page 1